OncoMatch/Clinical Trials/NCT04135807
Implantable Microdevice In Primary Brain Tumors
Is NCT04135807 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Microdevice for grade ii glioma.
Treatment: Microdevice — This pilot study will assess the safety and feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in malignant brain tumors. * The device involved in this study is called a microdevice. * The drugs used in this study will only include drugs already used systemically for the treatment of gliomas.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Required: Stage II, III, IV (WHO grade)
Grade: IIIIIIV (WHO)
WHO grade II-IV glioma
Prior therapy
Cannot have received: chemotherapy
Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas) prior to entering the study
Cannot have received: radiotherapy
Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas) prior to entering the study
Cannot have received: investigational agent
Participants who are receiving any other investigational agents
Lab requirements
Blood counts
Leukocytes ≥ 3,000/mcL; Absolute neutrophil count ≥ 1,500/mcL; Platelets ≥ 100,000/mcL
Kidney function
Creatinine within normal institutional limits OR Creatinine clearance ≥ 60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal
Liver function
Total bilirubin within normal institutional limits; AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional upper limit of normal
Participants must have normal organ and marrow function as defined below: * Leukocytes ≥ 3,000/mcL * Absolute neutrophil count ≥ 1,500/mcL * Platelets ≥ 100,000/mcL * Total bilirubin within normal institutional limits * AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional upper limit of normal * Creatinine within normal institutional limits OR * Creatinine clearance ≥ 60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify